News from AstraZeneca About COVID-19 Vaccine, AZD1222
From AstraZeneca (AZN) we learned that its COVID-19 vaccine, AZD1222, which is being developed in collaboration with Oxford University, has produced a similar immune response in older and younger adults. A spokesman from the firm stated that the results have further built the body of evidence for the safety and immunogenicity of AZD1222.
On October 23, 2020 AstraZeneca’s vaccine, AZD1222, resumed trials across the world with regulators in the US, the UK, Brazil, South Africa and Japan confirming that it was safe to do so. The FDA has authorized the restart in the US following the resumption of trials in other countries in recent weeks. The FDA reviewed all safety data from trials globally and concluded it was safe to resume.